{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:47:04Z","timestamp":1787071624949,"version":"build-2736575974"},"reference-count":12,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      Investigators have compared progestin-primed ovarian stimulation (PPOS) and conventional stimulations in multiple studies, however, with contrasting observations with respect to\n                      <jats:italic toggle=\"yes\">in vitro<\/jats:italic>\n                      fertilisation (IVF) cycle outcomes. The extent of serum luteinising hormone (LH) suppression has not been studied much between the protocols.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim:<\/jats:title>\n                    <jats:p>The primary aim of this study was to compare IVF cycle outcomes in terms of oocyte yield, maturation rate, fertilisation rate, blastulation rate, implantation and cumulative pregnancy rate between gonadotropin-releasing hormone (GnRH) antagonist protocol and fixed PPOS protocol. The secondary aim was to compare the extent of pituitary suppression as reflected by serum LH before final oocyte maturation between both the protocols.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Settings and Design:<\/jats:title>\n                    <jats:p>This was a retrospective observational cohort study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>\n                      All ovarian stimulation cycles, either performed as GnRH-antagonist or as fixed PPOS, between 1\n                      <jats:sup>st<\/jats:sup>\n                      October 2023 and 15\n                      <jats:sup>th<\/jats:sup>\n                      July 2024, at a tertiary level IVF centre were included. Egg freezing cycles and donor egg cycles were excluded.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Statistical Analysis Used:<\/jats:title>\n                    <jats:p>\n                      Statistical tests applied were Student\u2019s\n                      <jats:italic toggle=\"yes\">t<\/jats:italic>\n                      -test two-tailed for interval\/ratio variables and the Chi-square test for nominal variables with a significance level of 0.05.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The total number of cycles was 189, of which 87 (46.03%) cycles were in the GnRH antagonist group and 102 (53.96%) in the PPOS group. The groups were similar with respect to age, anti-M\u00fcllerian hormone, body mass index as well as total gonadotropin consumption. There was no significant difference observed for the number of oocytes (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.92), maturation rate (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.07), fertilisation rate (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.84), blastulation rate (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.52), implantation rate (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.36) and cumulative pregnancy rate (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.63). The serum LH values before final oocyte maturation (suppressed LH) were similar (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.09) in both the protocols.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>IVF cycle outcomes with respect to oocyte yield, maturation rate, fertilisation rate, blastulation rate, implantation rates and cumulative pregnancy were comparable between GnRH antagonist and PPOS cycles. Furthermore, the extent of pituitary suppression, reflected by the serum LH levels before final oocyte maturation, was similar between the groups as observed in our analysis. However, these findings need to be validated by prospective studies or randomised trials with equal patient division.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jhrs.jhrs_97_25","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:00:10Z","timestamp":1758772810000},"page":"136-140","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Gonadotropin-releasing Hormone Antagonist versus Fixed Progestin-Primed Ovarian Stimulation in In vitro Fertilisation: A Cohort Study"],"prefix":"10.4103","volume":"18","author":[{"given":"Manjushri Amol","family":"Kothekar","sequence":"first","affiliation":[{"name":"ART Fertility Clinic, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richa A.","family":"Jagtap","sequence":"additional","affiliation":[{"name":"ART Fertility Clinic, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parul","family":"Katiyar","sequence":"additional","affiliation":[{"name":"ART Fertility Clinic, Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Human M.","family":"Fatemi","sequence":"additional","affiliation":[{"name":"ART Fertility Clinics, UAE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Lawrenz","sequence":"additional","affiliation":[{"name":"ART Fertility Clinics, UAE"},{"name":"Reproductive Medicine UZ Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,9,25]]},"reference":[{"key":"R1-20251001","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1093\/humrep\/15.11.2333","article-title":"Dose-finding study of triptorelin acetate for prevention of a premature LH surge in IVF: A prospective, randomized, double-blind, placebo-controlled study","volume":"15","author":"Janssens","year":"2000","journal-title":"Hum Reprod"},{"key":"R2-20251001","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.fertnstert.2015.03.022","article-title":"Medroxyprogesterone acetate is an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization","volume":"104","author":"Kuang","year":"2015","journal-title":"Fertil Steril"},{"key":"R3-20251001","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s12958-023-01124-3","article-title":"Progestin primed ovarian stimulation (PPOS) protocol yields lower euploidy rate in older patients undergoing IVF","volume":"21","author":"Pai","year":"2023","journal-title":"Reprod Biol Endocrinol"},{"key":"R4-20251001","doi-asserted-by":"crossref","first-page":"1117513","DOI":"10.3389\/fendo.2023.1117513","article-title":"Comparison of cumulative live birth rates between progestin-primed ovarian stimulation protocol and gonadotropin-releasing hormone antagonist protocol in different populations","volume":"14","author":"Zhou","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R5-20251001","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1093\/humupd\/dmaa040","article-title":"Progestins for pituitary suppression during ovarian stimulation for ART: A comprehensive and systematic review including meta-analyses","volume":"27","author":"Ata","year":"2021","journal-title":"Hum Reprod Update"},{"key":"R6-20251001","doi-asserted-by":"crossref","first-page":"103639","DOI":"10.1016\/j.rbmo.2023.103639","article-title":"Progestin-primed ovarian stimulation: For whom, when and how?","volume":"48","author":"Ata","year":"2024","journal-title":"Reprod Biomed Online"},{"key":"R7-20251001","doi-asserted-by":"crossref","first-page":"573","DOI":"10.23736\/S2724-606X.22.05176-4","article-title":"Role and effectiveness of progestins in pituitary suppression during ovarian stimulation for assisted reproductive technology: A systematic review and a meta-analysis","volume":"75","author":"Yildiz","year":"2023","journal-title":"Minerva Obstet Gynecol"},{"key":"R8-20251001","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.fertnstert.2019.12.024","article-title":"Progesterone is a physiological trigger of ovulatory gonadotropins","volume":"113","author":"Dozortsev","year":"2020","journal-title":"Fertil Steril"},{"key":"R9-20251001","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.fertnstert.2024.11.005","article-title":"Luteinizing hormone\u2019s critical role in ovarian stimulation","volume":"123","author":"Toner","year":"2025","journal-title":"Fertil Steril"},{"key":"R10-20251001","doi-asserted-by":"crossref","first-page":"837880","DOI":"10.3389\/fendo.2022.837880","article-title":"Outcomes of a GnRH agonist trigger following a GnRH antagonist or flexible progestin-primed ovarian stimulation cycle","volume":"13","author":"Kalafat","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R11-20251001","doi-asserted-by":"crossref","first-page":"102049","DOI":"10.1016\/j.jogoh.2020.102049","article-title":"A meta-analysis of the efficacy of progestin-primed ovarian stimulation with medroxyprogesterone acetate in ovulation induction in poor ovarian responders","volume":"50","author":"Cai","year":"2021","journal-title":"J Gynecol Obstet Hum Reprod"},{"key":"R12-20251001","first-page":"CD013827","article-title":"Progestogens for prevention of luteinising hormone (LH) surge in women undergoing controlled ovarian hyperstimulation as part of an assisted reproductive technology (ART) cycle","volume":"11","author":"Glujovsky","year":"2023","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Journal of Human Reproductive Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jhrs.jhrs_97_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:49:47Z","timestamp":1787068187000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jhrs.jhrs_97_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":12,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/jhrs.jhrs_97_25","relation":{},"ISSN":["0974-1208","1998-4766"],"issn-type":[{"value":"0974-1208","type":"print"},{"value":"1998-4766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"2025-05-19","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-05","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}